<DOC>
	<DOC>NCT01161836</DOC>
	<brief_summary>This is a Phase 1, multi-center, open-label study. During Segment 1, patients are administered a single IV administration of [14C]-iniparib. During Segment 2, patients are administered iniparib with or without additional chemotherapy. Acceptable chemotherapy regimens is limited to those for which previous experience with iniparib exists.</brief_summary>
	<brief_title>An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 ÂµCi)</brief_title>
	<detailed_description />
	<mesh_term>Iniparib</mesh_term>
	<criteria>Male or female patients with advanced solid tumors that are refractory to standard treatment or for which no standard treatment exists; patients must be at least 18 years old. Additional criteria are also required and should be evaluated by the research staff.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>